Trials / Completed
CompletedNCT02032745
Genomic Signatures to Predict Treatment Response
Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 277 (actual)
- Sponsor
- Medical University of Graz · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A genomic test was developed to predict chemo-sensitivity to taxane-anthracycline-based chemotherapy as neoadjuvant treatment. The primary aim of this study is to prospectively evaluate the microarray-based, genomic test as a predictor of axillary lymph node response. Also, to determine whether the probability of achieving negative axillary nodes, is sufficiently high for patients whose breast cancer is predicted to be chemo-sensitive to support omitting axillary dissection.
Conditions
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2014-01-10
- Last updated
- 2020-08-04
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT02032745. Inclusion in this directory is not an endorsement.